Answers are grounded in this paper and cite their sources.
Observational analysis shows epigallocatechin gallate improves cardiac function in metabolic disorders, suggesting it may protect against myocardial infarction outcomes.
Cardiovascular health is essential for human survival, yet it remains threatened by injuries associated with metabolic disorders, myocardial infarction, ischemia–reperfusion, and even general anesthesia. The development of a safe and effective cardioprotective agent would be of considerable value in diverse clinical settings. Epigallocatechin gallate (EGCG), the principal constituent of catechins, has garnered considerable attention owing to its diverse health benefits. As a natural antioxidant and anti-inflammatory agent, it has been shown in numerous studies to exert pronounced cardioprotective effects. In preclinical studies, EGCG not only protects the coronary arteries but also attenuates adverse cardiac remodeling, prevents regulated cell death of cardiomyocytes, and enhances cardiac function. In addition, clinical studies have confirmed its beneficial effects on metabolic disorders, endothelial dysfunction, and adverse cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: